Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors [0.03%]
展望LDHAs抑制剂的未来：单兵作战还是协同作战？
Weixi Yuan,Qiang Kang,Yin Zhao et al.
Weixi Yuan et al.
As a key enzyme in pyruvate metabolism, lactate dehydrogenase A (LDHA) has been extensively studied for its role in cellular energy regulation and disease pathology. Given its central role in the Warburg effect (cancer cells have a higher i...
Circulatory compromise as a potential mechanism of fatal hepatic failure during long-term selpercatinib therapy: pharmacokinetic and clinical insights [0.03%]
血液循环障碍可能是长期塞尔帕替尼治疗导致致命性肝衰竭的潜在机制：药代动力学和临床见解
Wataru Suzuki,Yoshito Gando,Junichi Tomomatsu et al.
Wataru Suzuki et al.
Selpercatinib is a selective RET inhibitor with established efficacy in RET-altered malignancies; however, data regarding its long-term safety and pharmacokinetic behavior remain limited. We report a case of fatal hepatic failure occurring ...
CDCP1-targeted antibody-drug conjugates and immunocytokines for cancer therapy [0.03%]
用于癌症治疗的CDCP1靶向抗体-药物偶联物和免疫细胞因子
Guangmao Mu,Mingcan Yu,Fulai Zhou et al.
Guangmao Mu et al.
Purpose: CUB domain-containing protein 1 (CDCP1) is an emerging tumor-associated surface antigen broadly expressed in solid tumors and linked to poor prognosis, making it an attractive target for selective therapeutic del...
Pharmacokinetic and pharmacodynamic sub-study of trans-arterial vs. intravenous gemcitabine in the TIGeR-PaC phase 3 clinical trial [0.03%]
TIGeR-PaC III期临床试验中经导管动脉和静脉给药吉西他滨的药代动力学和药效学亚组研究
Paula M Novelli,Emmanuel E Zervos,Amer H Zureikat et al.
Paula M Novelli et al.
Purpose: Localized intra-arterial delivery of gemcitabine (IAG) may provide advantages in terms of increased tissue concentration and decreased systemic dosing. We hypothesized IAG may result in decreased systemic gemcita...
Quantitative characterization of platelet count and alanine aminotransferase dynamics to inform personalized dosing in the first-in-human LP-184 trial [0.03%]
LP-184人体首次试验中用于指导个性化给药的血小板计数和丙氨酸氨基转移酶动态变化的量化特征
Jianli Zhou,Daruka Mahadevan,Jay Parekh et al.
Jianli Zhou et al.
Purpose: Safety evaluation in first-in-human (FIH) Phase 1 oncology trials is largely descriptive and provides limited quantitative insights. This study characterized the dynamics of platelet count (PLT) and alanine amino...
Pharmacological inhibition of store-operated calcium entry enhances sorafenib-induced antitumor effects in Huh7 hepatocellular carcinoma cells [0.03%]
药理学上通过抑制储存操作的钙摄取能够增强索拉非尼诱导的肝癌细胞(Huh7)的抗肿瘤效果
Beste Yurdacan Yasar,Elmasnur Yilmaz,Yasemin Erac
Beste Yurdacan Yasar
Purpose: Sorafenib remains a systemic treatment option for advanced hepatocellular carcinoma (HCC), but its clinical efficacy is limited by rapid development of adaptive cellular responses that promote cell survival and p...
Associations of body composition with neoadjuvant chemotherapy response, toxicity, and prognosis in breast cancer: a scoping review [0.03%]
乳腺癌新辅助化疗疗效、毒副反应及预后与机体成分关联性的系统综述研究
Samantha Ligertwood,Femi E Ayeni,Andrew Parsonson et al.
Samantha Ligertwood et al.
Background: Breast cancer is the leading cause of cancer-related death in women worldwide. There is increasing interest in using detailed body composition parameters, such as skeletal muscle mass and adiposity, to better ...
Ferroptosis suppression by MYC confers oxaliplatin resistance in colorectal cancer via FTH1 and GPX4 [0.03%]
MYC通过FTH1和GPX4抑制铁死亡从而诱导结直肠癌顺铂耐药性
Yucheng Wang,Yulan Chen,Che Li et al.
Yucheng Wang et al.
Purpose: Oxaliplatin resistance remains a major obstacle in the treatment of colorectal cancer (CRC). This study aimed to determine whether MYC contributes to oxaliplatin resistance by regulating ferroptosis and to clarif...
Dosing challenges for chemotherapy and immunotherapy in congenital achondroplasia: a case report and literature review [0.03%]
先天性软骨发育不全的化疗和免疫治疗剂量挑战：病例报告和文献回顾
Karolijn W M Groot Beumer,E M J Durlinger,S W J Zielhuis et al.
Karolijn W M Groot Beumer et al.
Introduction: Currently, no established guidelines exist for dosing chemotherapy or immunotherapy in patients with achondroplasia. Case: ...
A rare variant in DPYD c.812delT causes severe adverse events of S-1 in a patient with tongue cancer [0.03%]
DPYD c.812delT罕见变异型导致舌癌患者S-1不良反应事件严重化
Hiroki Ishimura,Atsushi Suehiro,Daiki Hira et al.
Hiroki Ishimura et al.
Dihydropyrimidine dehydrogenase (DPD), which is encoded by the DPYD gene, plays an important role in the metabolism of fluoropyrimidine (FP) drugs, including tegafur, in S-1. A decrease in DPD activity can cause severe FP-related toxicity. ...